---
document_datetime: 2023-09-21 17:14:14
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-ratiopharm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-ratiopharm-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.4326402
conversion_datetime: 2025-12-22 17:52:48.143616
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|-----------|
| IB/0018/G            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product | 31/07/2013                                                                       | SmPC, Annex II, Labelling and PL |           |

<!-- image -->

Clopidogrel ratiopharm Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu edicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                       |            |                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------|
| IAIN/0017 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                        | 05/04/2013 | n/a                               |
| N/0016    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                      | 03/12/2012 | PL                                |
| T/0015    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/08/2012 | 11/09/2012 SmPC, Labelling and PL |
| IAIN/0014 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                                                        | 04/04/2012 | n/a no longer                     |
| IB/0011   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH product | 22/07/2011 | SmPC                              |
| IB/0010   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                        | 29/04/2011 | SmPC, Annex II and PL             |

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| WS/0052   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To add a new active substance manufacturer. B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is supported by an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/11/2010 18/11/2010           |
| WS/0053/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. - To change the genotoxic impurities specifications of the active substance; - To replace the current analytical method for the determination of genotoxic impurities acid in the active substance and finished product with a new one; - To change the genotoxic impurities specifications of the finished product. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) product | 21/10/2010 21/10/2010 no longer |

<div style=\"page-break-after: always\"></div>

|          | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                             | longer                            |                                                                                                          |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|----------------------------------------------------------------------------------------------------------|
| A20/0008 | Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004, the European Commission requested on 18 March 2010, the opinion of the CHMP on measures necessary to ensure the quality of the above mentioned medicinal product further to GMP deficiencies of the API manufacturing site Glochem Industries Ltd. (Unit II).                                                                                                                                                                                                                                                                         | 18/03/2010 16/09/2010 no          | Please refer to the Assessment Report: Clopidogrel ratiopharm-H-1173-A20-08-Assessment Report-Article 20 |
| IB/0009  | To include information on the clopidogrel metabolism pathway, the role of CYP2C19 genetic polumorphism on clopidogrel variability of response and the potential interaction between clopidogrel and CYP2C19 inhibitors including some proton pump inhibitors. The MAH also took the oportunity to align to the originator products. Furthermore the marketing authorisation numbers were separated. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO product | 06/08/2010 SmPC, Labelling and PL |                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         | new additional data are submitted by the MAH                                                                                                                                                  |            |                                          |                                      |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------|--------------------------------------|
| II/0006 | To introduce a new active substance manufacturer. Quality changes                                                                                                                             | 21/01/2010 | 09/02/2010                               |                                      |
| II/0007 | To register a revised version of the ASMF for clopidogrel besilate from the existing active substance manufacturer, introducing changes in the manufacturing process of the active substance. | 21/01/2010 | 09/02/2010                               |                                      |
| IB/0004 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                      | 04/11/2009 | 04/11/2009 SmPC, Labelling and PL longer | Quality changes                      |
| IA/0001 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site:                                                                   | 14/10/2009 | n/a                                      | Primary packaging site - Solid forms |
| IA/0002 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms product                      | 14/10/2009 | n/a no                                   |                                      |
| IA/0003 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                              | 14/10/2009 | n/a Annex II and PL                      |                                      |
| IA/0005 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                                                                                                                    | 14/10/2009 | n/a                                      |                                      |

edicinal product no longer authorised